These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32139008)

  • 1. Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood.
    Chapman JR; Thoren KL
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101142. PubMed ID: 32139008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
    Foureau D; Bhutani M; Guo F; Rigby K; Leonidas M; Tjaden E; Fox A; Atrash S; Paul B; Voorhees PM; Usmani SZ
    Cancer Med; 2021 Oct; 10(20):6933-6936. PubMed ID: 34494717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies.
    Zajec M; Jacobs JFM; Groenen PJTA; de Kat Angelino CM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
    J Proteome Res; 2018 Mar; 17(3):1326-1333. PubMed ID: 29424538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
    Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
    Br J Haematol; 2020 Jun; 189(5):904-907. PubMed ID: 32026474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
    Murray DL; Puig N; Kristinsson S; Usmani SZ; Dispenzieri A; Bianchi G; Kumar S; Chng WJ; Hajek R; Paiva B; Waage A; Rajkumar SV; Durie B
    Blood Cancer J; 2021 Feb; 11(2):24. PubMed ID: 33563895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
    Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
    J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.
    Thoren KL
    Semin Hematol; 2018 Jan; 55(1):41-43. PubMed ID: 29759153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
    Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
    Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bringing mass spectrometry into the care of patients with multiple myeloma.
    Murray DL
    Int J Hematol; 2022 Jun; 115(6):790-798. PubMed ID: 35471500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation Between Kappa Prozone Effect and IgA Kappa M Proteins in Serum Free Light-Chain Assay.
    Turner KA; Eckelkamp LL; Kalass SJ; Martinez MA; Brewer HR; Hoyne JB; Snyder MR; Murray DL; Willrich MAV
    Clin Chem; 2019 Oct; 65(10):1327-1329. PubMed ID: 31387883
    [No Abstract]   [Full Text] [Related]  

  • 13. Measurable disease evaluation in patients with myeloma.
    Roshal M
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101154. PubMed ID: 32139019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic.
    Milani P; Murray DL; Barnidge DR; Kohlhagen MC; Mills JR; Merlini G; Dasari S; Dispenzieri A
    Am J Hematol; 2017 Aug; 92(8):772-779. PubMed ID: 28439985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma.
    Chae H; Han E; Yoo J; Lee J; Lee JJ; Cha K; Kim M; Kim Y; Lee SE; Min CK
    Clin Chim Acta; 2018 Apr; 479():7-13. PubMed ID: 29324245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.
    Barnidge DR; Dasari S; Botz CM; Murray DH; Snyder MR; Katzmann JA; Dispenzieri A; Murray DL
    J Proteome Res; 2014 Mar; 13(3):1419-27. PubMed ID: 24467232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of multiple myeloma (IgG, lambda-type)) with pathological plasmacytes and M-protein in the pleural fluid (author's transl)].
    Fukushima K; Ishimi H; Tsutsui D; Morioka S; Nishimura Y; Tanaka T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1979 Jul; 17(7):415-20. PubMed ID: 119889
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous Nodules in Multiple Myeloma. Cutaneous plasmacytoma associated with multiple myeloma.
    Gómez-Armayones S; Climent F; Servitje O
    Actas Dermosifiliogr; 2015 Sep; 106(7):581-2. PubMed ID: 25935193
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of a "Myeloma Risk Score" using a population-based registry on paraproteinemia and myeloma.
    Ong F; Hermans J; Noordijk EM; De Kieviet W; Seelen PJ; Wijermans PW; Kluin-Nelemans JC
    Leuk Lymphoma; 1997 Nov; 27(5-6):495-501. PubMed ID: 9477131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.